Biomea Fusion Inc
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral covalent small molecule drugs to treat patients with metabolic diseases in the United States. It's lead product candidate icovamenib, an orally bioavailable, potent, and covalent inhibitor of menin, a ubiquitously expressed scaffold protein that functions in histone modif… Read more
Biomea Fusion Inc (BMEA) - Total Liabilities
Latest total liabilities as of September 2025: $39.57 Million USD
Based on the latest financial reports, Biomea Fusion Inc (BMEA) has total liabilities worth $39.57 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Biomea Fusion Inc - Total Liabilities Trend (2019–2024)
This chart illustrates how Biomea Fusion Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Biomea Fusion Inc Competitors by Total Liabilities
The table below lists competitors of Biomea Fusion Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Coya Therapeutics, Inc. Common Stock
NASDAQ:COYA
|
USA | $4.76 Million |
|
Visiomed Group SA
PINK:VMDGF
|
USA | $9.40 Million |
|
Bursa De Valori Bucuresti SA
RO:BVB
|
Romania | RON64.32 Million |
|
Horizon Minerals Ltd
AU:HRZ
|
Australia | AU$110.94 Million |
|
Oxford Bank Corporation
PINK:OXBC
|
USA | $977.54 Million |
|
Genelux Corporation Common Stock
NASDAQ:GNLX
|
USA | $6.40 Million |
|
Synergy Innovation Co. Ltd
KQ:048870
|
Korea | ₩67.50 Billion |
Liability Composition Analysis (2019–2024)
This chart breaks down Biomea Fusion Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.18 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.53 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.72 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Biomea Fusion Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Biomea Fusion Inc (2019–2024)
The table below shows the annual total liabilities of Biomea Fusion Inc from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $28.36 Million | -7.58% |
| 2023-12-31 | $30.69 Million | +47.78% |
| 2022-12-31 | $20.77 Million | +200.03% |
| 2021-12-31 | $6.92 Million | -87.93% |
| 2020-12-31 | $57.36 Million | +19954.90% |
| 2019-12-31 | $286.00K | -- |